Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using13C-uracil as an in vivo probe

British Journal of Clinical Pharmacology

Volumn 60, Issue 6, 2005, Pages 584-593

  Ito, Suminobu ^a   Kawamura, Takeshi ^b   Inada, Makoto ^c   Inoue, Yoshiharu ^c   Hirao, Yukihiro ^c   Koga, Toshihisa ^c   Kunizaki, Jun Ichi ^c   Shimizu, Takefumi ^c   Sato, Hitoshi ^d  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIYAGI UNIVERSITY   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d SHOWA UNIVERSITY   (Japan)

Author keywords

13C ; Dihydropyrimidine dehydrogenase (DPD); Physiologically based pharmacokinetic (PBPK) model; Uracil

Indexed keywords

AMMONIA; BETA ALANINE; BETA UREIDOPROPIONIC ACID; CARBON 13; CARBON DIOXIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; DRUG METABOLITE; FLUOROURACIL; ISOTOPE; UNCLASSIFIED DRUG; URACIL;

ARTICLE; BREATH ANALYSIS; CHEMICAL REACTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; EXHALATION; GAS CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; PROCESS MODEL; SCINTISCANNING; SIDE EFFECT; TANDEM MASS SPECTROMETRY;

ADULT; BREATH TESTS; CARBON DIOXIDE; CARBON ISOTOPES; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; URACIL;

EID: 28244441304     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02472.x     Document Type: Article

References (43)

1. Sonoda T, Tatibana M. Metabolic fate of pyrimidines and purines in dietary nucleic acids ingested by mice. Biochim Biophys Acta 1978; 521: 55-66.
2. Traut TW, Loechel S. Pyrimidine catabolism: individual characterization of the three sequential enzymes with a new assay. Biochemistry 1984; 23: 2533-9.
3. Canellakis ES. Pyrimidine metabolism. Enzymatic pathway of uracil and thymine degradation. J Biol Chem 1956; 221: 315-31.
4. 14-labelled uracil, dihydrouracil and β-ureidopropionic acid in rat liver slices. J Biol Chem 1957; 226: 223-8.
5. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-37.
6. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
7. Ho DH, Townsend L, Luna MA, Bodey GP. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986; 6: 781-4.
8. Woodcock TM, Martin DS, Damin LA, Kemeny NE, Young CW. Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer 1980; 45: 1135-43.
9. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-6.
10. Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 1990; 48: 189-222.
11. Lyss AP, Lilenbaum RC, Harris BE, Diasio RB. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 1993; 11: 239-40.
12. Morrison GB, Bastian A, Dela Rosa T, Diasio RB, Takimoto CH. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 1997; 24: 83-8.
13. Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi Y, Watabe T. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 1997; 25: 270-3.
14. Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998; 287: 791-9.
15. Bakkeren JA, De Abre RA, Sengers RC, Gabreels FJ, Maas JM, Renier WO. Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency. Clin Chim Acta 1984; 140: 247-56.
16. Berger R, Stoker-de Vries SA, Wadman SK, Duran M, Beemer FA, de Bree PK, Weits-Binnerts JJ, Penders TJ, van der Woude JK. Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism. Clin Chim Acta 1984; 141: 227-34.
17. Wilcken B, Hammond J, Berger R, Wise G, James C. Dihydropyrimidine dehydrogenase deficiency: a further case. J Inherit Metab Dis 1985; 8: 115-6.
18. Graham DY, Klein PD, Evans DJ Jr, Evans DG, Alpert LC, Opekun AR, Boutton TW. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet 1987; 1: 1174-7.
19. Cutler AF, Havstad S, Ma CK, Blaser MJ, Perez-Perez GI, Schubert TT. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995; 109: 136-41.
20. Goddard AF, Logan RP. Urea breath tests for detecting Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 641-9.
21. 2-expiration, and DPD activity in the liver in normal and DPD-deficient dogs. Drug Metab Dispos 2005; 33: 381-7.
22. Sumi S, Kidouchi K, Kondou M, Hayashi K, Dobashi K, Kouwaki M, Togari H, Wada Y. Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine. Int J Mol Med 1998; 2: 477-82.
23. Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993; 104: 1640-7.
24. 2 kinetics in humans after oral application of sodium bicarbonate as a model for breath testing. Eur J Clin Invest 1993; 23: 91-6.
25. Maes BD, Ghoos YF, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G. Combined carbon-13-glycine/carbon-14-octanoic acid breath test to monitor gastric emptying rates of liquids and solids. J Nucl Med 1994; 35: 824-31.
26. 13C]octanoic acid breath test for gastric emptying of solids: accuracy, reproducibility, and comparison with scintigraphy. Gastroenterology 1997; 112: 1155-62.
27. 13C breath tests. Dig Dis Sci 1995; 40: 2200-6.
28. 13C]urea breath test for detection of gastric infection with Helicobacter spp in dogs. Am J Vet Res 1998; 59: 1364-9.
29. Gonzalez FJ, Fernandez-Salguero P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci 1995; 16: 325-7.
30. Ignoffo RJ. Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer. Am J Health Syst Pharm 1999; 56: 2417-28.
31. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Huntingdon) 2001; 15: 21-6.
32. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000; 61: 199-203.
33. Wasternack C. Degradation of pyrimidines and pyrimidine analogs-pathways and mutual influences. Pharmacol Ther 1980; 8: 629-51.
34. Charnick SB, Kawai R, Nedelman JR, Lemaire M, Niederberger W, Sato H. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development. J Pharmacokinet Biopharm 1995; 23: 217-29.
35. Sato H, Sugiyama Y, Sawada Y, Iga T, Hanano M. Physiologically based pharmacokinetics of radioiodinated human beta-endorphin in rats. An application of the capillary membrane-limited model. Drug Metab Dispos 1987; 15: 540-50.
36. Nagata O, Murata M, Kato H, Terasaki T, Sato H, Tsuji A. Physiological pharmacokinetics of a new muscle-relaxant, inaperisone, combined with its pharmacological effect on blood flow rate. Drug Metab Dispos 1990; 18: 902-10.
37. Sato H, Terasaki T, Mizuguchi H, Okumura K, Tsuji A. Receptor-recycling model of clearance and distribution of insulin in the perfused mouse liver. Diabetologia 1991; 34: 613-21.
38. Smith AE, Yamada EW. Dihydrouracil dehydrogenase of rat liver. Separation of hydrogenase and dehydrogenase activities. J Biol Chem 1971; 246: 3610-7.
39. Sumi S, Imaeda M, Kidouchi K, Ohba S, Hamajima N, Kodama K, Togari H, Wada Y. Population and family studies of dihydropyrimidinuria: prevalence, inheritance mode, and risk of fluorouracil toxicity. Am J Med Genet 1998; 78: 336-40.
40. Hamajima N, Kouwaki M, Vreken P, Matsuda K, Sumi S, Imaeda M, Ohba S, Kidouchi K, Nonaka M, Sasaki M, Tamaki N, Endo Y, De Abreu R, Rotteveel J, van Kuilenburg A, van Gennip A, Togari H, Wada Y. Dihydropyriminase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene. Am J Hum Genet 1998; 63: 717-26.
41. Diasio RB, Schuetz JD, Wallace HJ, Sommadossi JP. Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells. Cancer Res 1985; 45: 4900-3.
42. Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 1980; 28: 235-46.
43. Wagner JG, Gyves JW, Stetson PL, Walker-Andrews SC, Wollner IS, Cochran MK, Ensminger WD. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 1986; 46: 1499-506.